A double blind controlled study of clobazam for the treatment of anxiety in psychiatric outpatients

K. D. Charalampous, C. E. Sermas, W. A. Newsom, George Keepers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Clobazam, a 1,5 benzodiazepine, was compared to placebo in a double-blind randomized efficacy trial. The thirty patients in the trial had a diagnosis of anxiety neurosis which was at least moderately severe. Fourteen received a placebo and sixteen received the drug in increasing doses for one week. Comparison of the two groups on the basis of pre- and post-treatment Hamilton Anxiety Scores and Clinical Global Improvement Scores indicated definite superiority of clobazam over placebo in the treatment of anxiety. The most common side effects were drowsiness and dizziness.

Original languageEnglish (US)
Pages (from-to)779-785
Number of pages7
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume21
Issue number6
StatePublished - 1977
Externally publishedYes

Fingerprint

Double-Blind Method
Psychiatry
Outpatients
Anxiety
Placebos
Sleep Stages
Dizziness
Anxiety Disorders
Benzodiazepines
Therapeutics
Pharmaceutical Preparations
clobazam

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A double blind controlled study of clobazam for the treatment of anxiety in psychiatric outpatients. / Charalampous, K. D.; Sermas, C. E.; Newsom, W. A.; Keepers, George.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 21, No. 6, 1977, p. 779-785.

Research output: Contribution to journalArticle

@article{294a5f42f53046b692712dd72d2978ad,
title = "A double blind controlled study of clobazam for the treatment of anxiety in psychiatric outpatients",
abstract = "Clobazam, a 1,5 benzodiazepine, was compared to placebo in a double-blind randomized efficacy trial. The thirty patients in the trial had a diagnosis of anxiety neurosis which was at least moderately severe. Fourteen received a placebo and sixteen received the drug in increasing doses for one week. Comparison of the two groups on the basis of pre- and post-treatment Hamilton Anxiety Scores and Clinical Global Improvement Scores indicated definite superiority of clobazam over placebo in the treatment of anxiety. The most common side effects were drowsiness and dizziness.",
author = "Charalampous, {K. D.} and Sermas, {C. E.} and Newsom, {W. A.} and George Keepers",
year = "1977",
language = "English (US)",
volume = "21",
pages = "779--785",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - A double blind controlled study of clobazam for the treatment of anxiety in psychiatric outpatients

AU - Charalampous, K. D.

AU - Sermas, C. E.

AU - Newsom, W. A.

AU - Keepers, George

PY - 1977

Y1 - 1977

N2 - Clobazam, a 1,5 benzodiazepine, was compared to placebo in a double-blind randomized efficacy trial. The thirty patients in the trial had a diagnosis of anxiety neurosis which was at least moderately severe. Fourteen received a placebo and sixteen received the drug in increasing doses for one week. Comparison of the two groups on the basis of pre- and post-treatment Hamilton Anxiety Scores and Clinical Global Improvement Scores indicated definite superiority of clobazam over placebo in the treatment of anxiety. The most common side effects were drowsiness and dizziness.

AB - Clobazam, a 1,5 benzodiazepine, was compared to placebo in a double-blind randomized efficacy trial. The thirty patients in the trial had a diagnosis of anxiety neurosis which was at least moderately severe. Fourteen received a placebo and sixteen received the drug in increasing doses for one week. Comparison of the two groups on the basis of pre- and post-treatment Hamilton Anxiety Scores and Clinical Global Improvement Scores indicated definite superiority of clobazam over placebo in the treatment of anxiety. The most common side effects were drowsiness and dizziness.

UR - http://www.scopus.com/inward/record.url?scp=0017735616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017735616&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0017735616

VL - 21

SP - 779

EP - 785

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 6

ER -